Entrada Therapeutics enters into $150M at-the-market offering agreement with Cowen

Entrada Therapeutics, Inc.

Entered into sales agreement with Cowen and Company for at-the-market offering of up to $150M in common stock.
Cowen will receive a commission of up to 3.0% of gross sales proceeds; Company not obligated to sell any shares.
Offering made under existing effective shelf registration statement (S-3) filed November 2022.
Shares will be sold on Nasdaq or other trading markets, subject to instructions and conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Entrada Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $150.0 million (effective 2023-09-29).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: up to $150.0 million
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, Entrada Therapeutics, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, acting as the Company’s agent and/or principal (the “Sales Agent”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million

View on SEC.gov

270 material agreements filed in the last 30 days. Browse all material agreements →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-105351

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.